Celgene Corp (CELG) 110.98 $CELG 3 Biotech Stocks You

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2015 at 1:53 PM

Celgene Corp (CELG) 110.98 $CELG

3 Biotech Stocks You Don't Have to Babysit
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Tue Nov 17, 9:31AM CST
Image by Juliacdrd via pixabay Biotech stocks tend to be a risky breed, since even though they can offer investors strong returns, they usually walk hand in hand with huge volatility. To see this reality in action, look no further than the...
GILD: 104.18 (+0.37), IBB: 329.05 (+4.16), AMGN: 157.88 (+3.38), CELG: 110.98 (+0.84)

Covered Call Alerts For Disney, Celgene, Petrobras, Shake Shack and Exelixis Released By InvestorsObserver
PR Newswire - Tue Nov 17, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for DIS, CELG, PBR, SHAK and EXEL.
PBR: 4.92 (-0.05), SHAK: 41.99 (-1.43), DIS: 116.76 (+0.84), EXEL: 5.60 (+0.12), CELG: 110.98 (+0.84), CELGZ: 1.10 (unch)

Why Juno Therapeutics Inc. Jumped 26% in October
Brian Feroldi, The Motley Fool - Motley Fool - Mon Nov 16, 3:01PM CST
What: Shares of Juno Therapeutics , a mid-cap biotech with a focus on chimeric antigen receptor to train T cells, or CAR-T therapy, treated its investors to yet another strong month. Shares traded more than 26% higher in October, according to data...
JUNO: 53.12 (-0.35), CELG: 110.98 (+0.84)

Clovis Blowup Conjures Bad Biotech Memories of ImClone Darkness
at The Street - Mon Nov 16, 11:20AM CST
The last thing the biotech industry needs today is another hit to investor credibility. Clovis isn't helping.
BLUE: 81.60 (+7.15), ZFGN: 14.66 (-0.06), BIIB: 281.03 (-2.50), VRX: 71.59 (-1.73), CLVS: 27.57 (-2.67), AZN: 33.27 (+0.49), FOLD: 9.39 (-0.74), CELG: 110.98 (+0.84)

Next Support Level for Celgene (CELG) is $104.68
Comtex SmarTrend(R) - Mon Nov 16, 10:21AM CST
Celgene (NASDAQ:CELG) has opened bearishly below the pivot of $108.73 today and has reached the first level of support at $106.09. Investors may be interested in a cross of the next downside pivot targets of $104.68 and $100.63.
CELG: 110.98 (+0.84)

Juno Therapeutics Finishes Q3 in Good Shape Where It Matters Most
Keith Speights, The Motley Fool - Motley Fool - Sat Nov 14, 11:19AM CST
Image Source: Juno Therapeutics Can a company report its quarterly financial results and most of the numbers not be all that important? Absolutely -- if that company is a development-stage biotech. Juno Therapeutics announced its third-quarter...
JUNO: 53.12 (-0.35), CELG: 110.98 (+0.84)

Celgene Falls 2.84% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Nov 12, 4:59PM CST
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $108.98 to a high of $112.00. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $112.15 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 110.98 (+0.84)

Celgene (CELG) Stock Showing Signs of a Downtrend
at The Street - Thu Nov 12, 3:00PM CST
Our indicators are pointing to lower prices for Celgene (CELG).
CELG: 110.98 (+0.84)

Celgene Showing Signs of a Downtrend (Plus: BBY, ANTM, NWL)
at The Street - Thu Nov 12, 2:30PM CST
Our indicators are pointing to lower prices for CELG.
ANTM: 135.87 (+0.81), NWL: 43.63 (+0.39), BBY: 30.91 (-0.72), CELG: 110.98 (+0.84)

4 Observations You May Have Overlooked in Celgene's Q3 Earnings Report
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 12, 5:58AM CST
Image source: U.S. Food and Drug Administration. The wait is over. Last Thursday, before the opening bell, biotech blue-chip stock Celgene reported its third-quarter earnings results. Expectations were high for the fast-growing drugmaker, but...
MRK: 53.88 (+0.18), AMGN: 157.88 (+3.38), BMY: 65.82 (+0.80), CELG: 110.98 (+0.84)

Juno Therapeutics Posts Wider-than-Expected Loss in Q3
Arpita Dutt - Zacks Investment Research - Wed Nov 11, 8:52AM CST
Investor focus will remain on Juno's (JUNO) cash burn and its pipeline progress.
ACHN: 9.98 (-0.01), JUNO: 53.12 (-0.35), BXLT: 34.14 (-0.34), CELG: 110.98 (+0.84)

3 Stocks We're Never Selling
Todd Campbell, Tyler Crowe, and Andrés Cardenal, The Motley Fool - Motley Fool - Tue Nov 10, 2:39PM CST
It's been proven time and time again that long-term investing outperforms short-term trading, and with that in mind, we asked some of our top Motley Fool contributors to highlight stocks they have no intention of selling from their portfolios. ...
WM: 52.63 (+0.07), CELG: 110.98 (+0.84)

3 Midsize Drug Stocks Moving On Q3 Reports
at Investor's Business Daily - Tue Nov 10, 12:34PM CST
Midcap drugmakers Jazz Pharmaceuticals, Halozyme Therapeutics and Depomed were moving in the stock market Tuesday after they reported Q3 earnings late Monday, rounding out a mixed earnings season for the beleaguered sector. Jazz Pharmaceuticals...
JNJ: 101.55 (+0.33), HALO: 15.65 (+0.07), JAZZ: 142.01 (+4.63), HZNP: 18.70 (-0.26), DEPO: 19.09 (-0.30), CELG: 110.98 (+0.84)

Epizyme's Q3 Loss Wider-Than-Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 8:34AM CST
Epizyme (EPZM) reported a wider-than-expected loss in the third quarter of 2015.
ICPT: 171.20 (-3.13), EPZM: 15.08 (-0.26), BXLT: 34.14 (-0.34), CELG: 110.98 (+0.84)

'Mad Money' Lightning Round: Buy Delta Air Lines and Nordic American Tanker
at The Street - Tue Nov 10, 5:00AM CST
Cramer likes certain airlines but doesn't want to be in apparel.
PRTY: 11.96 (-0.74), DAL: 48.69 (+0.76), KMB: 119.40 (-0.13), LUV: 46.35 (+0.61), CELG: 110.98 (+0.84), LGF: 37.73 (+0.20), CHK: 6.03 (-0.31), TOO: 12.76 (-0.23), NAT: 14.98 (-0.42), AAL: 42.73 (-0.10), CRI: 84.04 (-1.16), EROS: 8.08 (+0.59), SWHC: 17.37 (-0.12)

Jim Cramer's 'Mad Money' Recap: Opportunities as Rates Rise
at The Street - Mon Nov 09, 7:10PM CST
Cramer says investors shouldn't panic when rates rise.
VRX: 71.59 (-1.73), CYBR: 37.79 (-0.85), PRTY: 11.96 (-0.74), DAL: 48.69 (+0.76), KMB: 119.40 (-0.13), PCL: 48.68 (+1.56), CELG: 110.98 (+0.84), LUV: 46.35 (+0.61), LGF: 37.73 (+0.20), CHK: 6.03 (-0.31), TOO: 12.76 (-0.23), HZNP: 18.70 (-0.26), NAT: 14.98 (-0.42), WY: 30.95 (+0.81), APA: 49.98 (-0.51), COST: 159.62 (+3.17), AAL: 42.73 (-0.10), HAWK: 45.22 (+1.13), CRI: 84.04 (-1.16), GPS: 24.90 (-0.48), EROS: 8.08 (+0.59), SWHC: 17.37 (-0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

National Showrooms Expands into Virginia with Key Buy

A New Chapter for Greenwich Kitchens I'll tell you what's catching my eye this time—National Kitchen & Bath Showrooms are making their move into Virginia by snapping up Greenwich Kitchens, a well-regarded name in the local kitchen and bath scene. Founded back in '78, Greenwich Kitchens has been a staple in the Virginia Beach and Hampton Roads areas for nearly half a...

OppFi Readies Q3 Earnings; Investors Eye Financials

What's Unfolding at OppFi? Mark your calendars, folks. October 28th is the day OppFi (NYSE: OPFI) pulls the curtain back on its third-quarter 2026 earnings. For the uninitiated, we're talking about a tech-driven finance platform that's been making waves by providing financial solutions for everyday Americans. And you bet we're all ears for what those numbers say. Details...

Plata Hits $1 Billion ARR in Record Digital Bank Growth

Plata Rocks the Boat with Rapid Revenue Growth When a digital bank like Plata rakes in $1 billion in Annual Recurring Revenue (ARR) within just 3.5 years, you can't just shrug it off. That's blazing fast by any standard, especially for a financial institution. Emerging from Mexico, this bank's rocket-like ascent is flinging the doors wide open for what's possible in the...

INSPIRE 2026: Luxury Hotel Trends and Investments

Luxury Hotels: Where's the Money Headed? All eyes on Orlando this December 15–16, where the International Luxury Hotel Association (ILHA) is calling the shots. INSPIRE 2026 is the marquee event of the year for luxury hospitality, and it ain't just about starry chandeliers and velvet drapes. We're talking real capital shifts, margins pinching tighter, and a future...

Security Leadership Faces Unseen Identity Risks

Rocky Road in Identity Security Catch this: you're a security honcho, thinking you've forked over enough dough to lock down human and machine identities. But now, it turns out, most of your kind still don't have a full handle on who or what is poking around your systems. Talk about a wrench in the gears. This latest report from Oak drags the reality into the limelight:...

Food Trends Tease: 2027 sofi™ Awards' 75 Finalists

The Specialty Food Scene Heats Up Today’s world doesn’t rest when it comes to innovation, and the same goes for the tantalizing realm of specialty foods. Hot off the press, the Specialty Food Association (SFA) just rolled out the red carpet for its 75 finalists in the 2027 sofi™ Awards. These are the future taste shapers set to take center stage at the Winter...

Art Print Paper: Finding the Perfect Match for Masterpieces

You ever stand in a gallery and notice how some art just lights up the room while others barely get a second glance? Well, a lot of that magic starts with an unsung hero—paper choice. I came across this bit from HelloNation diving into what makes paper selection a cornerstone for fine art prints. Now, I ain't an artist, but even a bruiser trader like me can see the...

Tumor Ablation Market: Charting a Billion-Dollar Surge

Cancer's Unforgiving Climb: Opportunity Amidst Challenge Looking at the current state of the global tumor ablation market, one thing's clear—it's on a sort of upward swing you'd expect trains to make, riding the rails of rising cancer rates and technological advancements. At least that's what the folks at Wissen Research are banking on, projecting a leap to $1.8 billion...

Meitav Tops 2025 Service Index with Stellar Growth

Meitav’s Leap to The Summit Damn, it's a wild market when a pension fund provider snatches the crown. But here we are, looking at Meitav Provident Funds and Pension Ltd., standing proudly as Israel's top dog in the 2025 Service Index for pension funds. We're talking a jump from fourth to numero uno, folks, with a hefty score of 83 out of 100. And don't sleep on their...

DOCS Faces Investor Legal Battle for Alleged Misconduct

The DOCS Predicament: Investors Facing Class Action Doximity, Inc., trading as NYSE:DOCS, finds itself in hot water again as shareholders gear up for a legal skirmish over alleged securities fraud. Schall, Brown & Schwartz LLP, the firm rallying the shareholders, has fired the opening salvo, pointing fingers at Doximity for cooking the books about their Newsfeed’s...